ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue-Reference-Cited by-同舟云学术

ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue

Published:2023-09-28 Issue: Volume: Page:
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Mersiades Antony J¹²^ORCID,Solomon Benjamin J³^ORCID,Thomas David M⁴⁵^ORCID,Lee Chee K¹⁶^ORCID,Cummins Michelle M¹^ORCID,Sebastian Lucille¹,Ballinger Mandy L⁴⁵^ORCID,Collignon Emily⁴,Turnbull Olivia MH⁴,Yip Sonia¹,Morton Rachael L¹^ORCID,Brown Chris¹^ORCID,Wheeler Patrick J¹,Itchins Malinda⁷^ORCID,Simes R John¹^ORCID,Pavlakis Nick⁷^ORCID

Affiliation:

1. National Health & Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Camperdown, NSW, 2050, Australia

2. Department of Medical Oncology, Northern Beaches Hospital, Frenchs Forest, NSW, 2086, Australia

3. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, 3001, Australia

4. Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia

5. St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Randwick, NSW, 2031, Australia

6. Department of Medical Oncology, St George Hospital, Kogarah, NSW, 2217, Australia

7. Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St Leonards, NSW, 2065, Australia

Abstract

ASPiRATION is a national prospective observational cohort study assessing the feasibility, clinical and economic value of up-front tissue-based comprehensive genomic profiling (CGP) to identify actionable genomic alterations in participants with newly diagnosed metastatic non-squamous non-small-cell lung cancer in Australia. This study will enrol 1000 participants with tumor available for CGP and standard of care molecular testing ( EGFR/ ALK/ROS1). Participants with actionable variants may receive novel targeted treatments through ASPiRATION-specific substudies, other trials/programs. Clinical outcome data will be collected for a minimum of 2 years. Study outcomes are descriptive, including the ability of CGP to identify additional actionable variants, leading to personalized treatment recommendations, and will describe the feasibility, efficiency, cost and utility of implementation of CGP nationally.

Funder

Australian Government Medical Research Future Fund

Roche Products Pty Limited

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2023-0366

Reference24 articles.

1. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

2. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study